Skip to main content
ZheJiang Tailin Bioengineering Co.,Ltd logo

ZheJiang Tailin Bioengineering Co.,Ltd — Investor Relations & Filings

Ticker · 300813 ISIN · CNE100003S89 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 990 across all filing types
Latest filing 2026-04-16 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 300813

About ZheJiang Tailin Bioengineering Co.,Ltd

https://www.tailingood.com

ZheJiang Tailin Bioengineering Co.,Ltd. specializes in the research, development, and manufacturing of high-tech equipment for life sciences and pharmaceutical engineering. The company provides integrated solutions for microbial control, sterility testing, and aseptic processing. Its core product portfolio includes sterility test canisters and pumps, microbial limit testing systems, and hydrogen peroxide vapor (VHP) decontamination units. Tailin also develops advanced isolator technology for containment and aseptic applications, alongside analytical instruments such as Total Organic Carbon (TOC) analyzers and filter integrity testers. These products are designed to meet international regulatory standards, including GMP, USP, and EP. The company serves sectors such as biopharmaceuticals, medical devices, and laboratory research, focusing on product safety and quality through specialized engineering and microbial detection technologies.

Recent filings

Filing Released Lang Actions
国浩律师（杭州）事务所关于浙江泰林生物技术股份有限公司2025年年度股东会法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2025 Annual General Meeting (AGM) of Zhejiang Tailin Biotechnology Co., Ltd. It details the procedures for convening and holding the AGM, the qualifications of attendees, the agenda items discussed, and the voting results for each agenda item. The document includes extensive voting results and legal compliance checks related to the AGM. It is not the actual annual report or financial statements but a legal opinion on the AGM process and voting outcomes. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is substantial and contains detailed voting results, not just an announcement of a report publication or a brief notice, so it is not an RPA or RNS. Hence, the classification is DVA with high confidence.
2026-04-16 Chinese
国浩律师（杭州）事务所关于浙江泰林生物技术股份有限公司2026年员工持股计划之法律意见书
Capital/Financing Update Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2026 employee stock ownership plan of Zhejiang Tailin Biotechnology Co., Ltd. It discusses the legal compliance, procedures, and regulatory adherence related to the employee stock ownership plan. The document is not a financial report, earnings release, or management discussion. It is a legal opinion specifically related to a capital/financing activity (employee stock ownership plan). It is not a mere announcement or a proxy solicitation but a detailed legal opinion on the employee stock ownership plan, which is a capital/financing update. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (9099 characters) and content confirm it is a substantive legal opinion, not just an announcement or certification.
2026-04-10 Chinese
关于回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of the company's share repurchase plan. It details the board meeting approval, the repurchase price limit, the total funds allocated, and the implementation period. It explicitly states that as of the date, no shares have been repurchased yet, and the company will disclose further information as repurchases occur. This fits the category of a Transaction in Own Shares (POS) filing, which covers announcements about share buybacks or sales by the company itself. The document is short and focused solely on the repurchase progress, not a full financial report or other type of filing.
2026-04-02 Chinese
关于取得专利证书及计算机软件著作权登记证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Zhejiang Tailin Biotechnology Co., Ltd. regarding the acquisition of patent certificates and computer software copyright registration certificates by its subsidiaries. It details the patent names, types, application numbers, and dates, as well as software copyright registration details. The document explicitly states it is an announcement about obtaining intellectual property rights and does not contain financial data, management changes, voting results, or other report types. It is a regulatory announcement about intellectual property achievements, which does not fit into categories like Annual Report, Earnings Release, or Management Reports. Given the nature and length (1095 characters), it is best classified under Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2026-03-30 Chinese
回购报告书
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement from Zhejiang Tailin Biotechnology Co., Ltd. regarding a share repurchase plan. It includes specifics about the repurchase purpose, conditions, price range, quantity, funding sources, implementation period, risk warnings, and board authorizations. The document explicitly refers to a '回购报告书' (Repurchase Report) and discusses the company's plan to buy back shares for an employee stock ownership plan. It also mentions the opening of a dedicated repurchase securities account and the company's commitment to disclose repurchase progress. The content is focused on the company's share buyback activities and related disclosures, which aligns with the category of Transaction in Own Shares (POS). The document length (7712 characters) and detailed content confirm it is the actual report of the repurchase plan, not merely an announcement of a report publication or a brief notice. Therefore, the appropriate classification is POS (Transaction in Own Shares).
2026-03-30 Chinese
关于回购股份事项前十名股东及前十名无限售条件股东持股情况的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding the shareholding details of the top ten shareholders and top ten unrestricted shareholders prior to a share repurchase plan. It references a previous announcement about the share repurchase plan and provides detailed shareholding data as of a specific date. The content focuses on shareholding information related to a share buyback, not on financial results, management changes, or voting results. This fits the category of a Transaction in Own Shares (POS) filing, which covers company announcements about share repurchases or sales of own shares. The document length is short and it is not a report publication or certification, so it is not RPA or RNS. Therefore, the correct classification is POS with high confidence.
2026-03-30 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.